sulfadoxine-pyrimethamine and chlorproguanil-dapsone — Competitive Intelligence Brief

sulfadoxine-pyrimethamine and chlorproguanil-dapsone (sulfadoxine-pyrimethamine and chlorproguanil-dapsone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifolate antimalarial combination. Area: Infectious Disease.

phase 3 Antifolate antimalarial combination Dihydrofolate reductase; dihydropteroate synthase Infectious Disease Small molecule

Target snapshot

sulfadoxine-pyrimethamine and chlorproguanil-dapsone (sulfadoxine-pyrimethamine and chlorproguanil-dapsone) — London School of Hygiene and Tropical Medicine. This combination of two antimalarial drugs works by inhibiting folate synthesis in Plasmodium parasites, preventing DNA replication and parasite growth.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
sulfadoxine-pyrimethamine and chlorproguanil-dapsone TARGET	sulfadoxine-pyrimethamine and chlorproguanil-dapsone	London School of Hygiene and Tropical Medicine	phase 3	Antifolate antimalarial combination	Dihydrofolate reductase; dihydropteroate synthase
Quinine plus sulfadoxine-pyrimethamine	Quinine plus sulfadoxine-pyrimethamine	Albert Schweitzer Hospital	marketed	Antimalarial combination	Plasmodium DNA/protein synthesis; dihydrofolate reductase; dihydropteroate synthase
TMX-SMX (Bactrim(R))	TMX-SMX (Bactrim(R))	Department of Medical Services Ministry of Public Health of Thailand	marketed	Sulfonamide antibiotic combination	Dihydrofolate reductase; dihydropteroate synthase
Sulfadoxine pyrimethamine	Sulfadoxine pyrimethamine	Radboud University Medical Center	marketed	Antifolate antimalarial	Dihydrofolate reductase; dihydropteroate synthase
Sulphadoxine-Pyrimethamine	Sulphadoxine-Pyrimethamine	ORIYOMI OMOTOYOSI AKINYOTU	marketed	Antifolate antimalarial	Dihydrofolate reductase; dihydropteroate synthase
Sulfadoxine-pyrimethamine/folic acid	Sulfadoxine-pyrimethamine/folic acid	Centers for Disease Control and Prevention	marketed	Antifolate antimalarial	Dihydrofolate reductase; dihydropteroate synthase
Artesunate + Sulfadoxine-Pyrimethamine	Artesunate + Sulfadoxine-Pyrimethamine	Sanofi	marketed	Antimalarial combination	Plasmodium falciparum (multiple targets: artemisinin-induced oxidative stress; dihydrofolate reductase; dihydropteroate synthase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifolate antimalarial combination class)

1. London School of Hygiene and Tropical Medicine · 4 drugs in this class
2. Kenya Medical Research Institute · 1 drug in this class
3. Swiss Tropical & Public Health Institute · 1 drug in this class